Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

Bente Glintborg; Tina Marie Kringelbach; E. Høgdall; Inge Juul Sørensen; Dorte Vendelbo Jensen; A. G. Loft; O. Hendricks; I. M. Jensen Hansen; N. Bolstad; Kathrine Lederballe Grøn; G. Eng; C. Enevold; C. H. Nielsen; D. Warren; G. Goll; J. Gehin; Julia Sidenius Johansen; Merete Lund Hetland

Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

Bente Glintborg, Tina Marie Kringelbach, E. Høgdall, Inge Juul Sørensen, Dorte Vendelbo Jensen, A. G. Loft, O. Hendricks, I. M. Jensen Hansen, N. Bolstad, Kathrine Lederballe Grøn, G. Eng, C. Enevold, C. H. Nielsen, D. Warren, G. Goll, J. Gehin, Julia Sidenius Johansen, Merete Lund Hetland

Department for Rheumatology and Spine Diseases

Original language	English
Article number	THU0123
Journal	Annals of the Rheumatic Diseases
Volume	75
Issue number	Suppl. 2
Pages (from-to)	224
Number of pages	1
ISSN	0003-4967
Publication status	Published - 2016

Cite this

Glintborg, B., Kringelbach, T. M., Høgdall, E., Sørensen, I. J., Jensen, D. V., Loft, A. G., Hendricks, O., Jensen Hansen, I. M., Bolstad, N., Grøn, K. L., Eng, G., Enevold, C., Nielsen, C. H., Warren, D., Goll, G., Gehin, J., Johansen, J. S., & Hetland, M. L. (2016). Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. Annals of the Rheumatic Diseases, 75(Suppl. 2), 224. Article THU0123.

Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. / Glintborg, Bente; Kringelbach, Tina Marie; Høgdall, E. et al.
In: Annals of the Rheumatic Diseases, Vol. 75, No. Suppl. 2, THU0123, 2016, p. 224.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Glintborg, B, Kringelbach, TM, Høgdall, E, Sørensen, IJ , Jensen, DV, Loft, AG, Hendricks, O, Jensen Hansen, IM, Bolstad, N, Grøn, KL, Eng, G, Enevold, C, Nielsen, CH, Warren, D, Goll, G, Gehin, J, Johansen, JS & Hetland, ML 2016, 'Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry', Annals of the Rheumatic Diseases, vol. 75, no. Suppl. 2, THU0123, pp. 224.

Glintborg B, Kringelbach TM, Høgdall E, Sørensen IJ , Jensen DV, Loft AG et al. Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. Annals of the Rheumatic Diseases. 2016;75(Suppl. 2):224. THU0123.

Glintborg, Bente ; Kringelbach, Tina Marie ; Høgdall, E. et al. / Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. In: Annals of the Rheumatic Diseases. 2016 ; Vol. 75, No. Suppl. 2. pp. 224.

@article{07b1609cf91b4036b4846cf44d7b0425,

title = "Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry",

author = "Bente Glintborg and Kringelbach, \{Tina Marie\} and E. H{\o}gdall and S{\o}rensen, \{Inge Juul\} and Jensen, \{Dorte Vendelbo\} and Loft, \{A. G.\} and O. Hendricks and \{Jensen Hansen\}, \{I. M.\} and N. Bolstad and Gr{\o}n, \{Kathrine Lederballe\} and G. Eng and C. Enevold and Nielsen, \{C. H.\} and D. Warren and G. Goll and J. Gehin and Johansen, \{Julia Sidenius\} and Hetland, \{Merete Lund\}",

year = "2016",

language = "English",

volume = "75",

pages = "224",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "Suppl. 2",

}

TY - ABST

T1 - Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

AU - Glintborg, Bente

AU - Kringelbach, Tina Marie

AU - Høgdall, E.

AU - Sørensen, Inge Juul

AU - Jensen, Dorte Vendelbo

AU - Loft, A. G.

AU - Hendricks, O.

AU - Jensen Hansen, I. M.

AU - Bolstad, N.

AU - Grøn, Kathrine Lederballe

AU - Eng, G.

AU - Enevold, C.

AU - Nielsen, C. H.

AU - Warren, D.

AU - Goll, G.

AU - Gehin, J.

AU - Johansen, Julia Sidenius

AU - Hetland, Merete Lund

PY - 2016

Y1 - 2016

M3 - Conference abstract in journal

SN - 0003-4967

VL - 75

SP - 224

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl. 2

M1 - THU0123

ER -